Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sunovion’s COPD Med Slapped with FDA Complete Response Letter
The US FDA has issued a complete response letter to Sunovion Pharmaceuticals’ chronic obstructive pulmonary disease (COPD) treatment SUN-101/eFlow (glycopyrrolate), rejecting the drug’s approval at this stage. Sunovion, a US subsidiary of Sumitomo Dainippon Pharma, on May 26 revealed that…
To read the full story
Related Article
- Nebulized COPD Med Lonhala Magnair Now Available in US: Sunovion
April 5, 2018
- FDA Clears Sunovion’s Nebulized COPD Drug
December 7, 2017
- FDA Accepts NDA Resubmission for Sunovion’s COPD Med
July 4, 2017
- PDUFA Date for COPD Drug Set for May 29, 2017: Sunovion
October 17, 2016
- Sunovion Submits US NDA for COPD Drug
August 2, 2016
BUSINESS
- Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
March 6, 2026
- Keytruda Maintains Top Spot for 29 Straight Months in February: Encise
March 6, 2026
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
- Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
- Ono Partners with Congruence on Neurology, Immunology Drug Discovery
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…